Design and results of PERSIST-1 trial of pacritinib for myelofibrosis by Ruben Mesa
Acute Lymphoblastic Leukemia
Acute Myeloid Leukemia
Chronic Lymphocytic Leukemia
Chronic Myeloid Leukemia
Diffuse Large B-Cell Lymphoma
View expert index
View all diseases
View all trials
View all medicines
EMMA Vienna 2017
View upcoming conferences
View previous conferences
What are the differences in health technology assessment (HTA) across Europe?
Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France, discusses the differences in the evaluation of value of new…
How can clinicians and nurses care for patients with oral graft-versus-host disease (GvHD)?
Nathaniel Treister, DMD, DMSc, from Brigham and Women's Hospital, Boston, MA, explains how clinicians and nurses can care for patients…
Can the cytomegalovirus be predicted by ELISpot assays?
Roy F. Chemaly, MD, of MD Anderson Cancer Centre, Houston, TX discusses the importance of ELISpot assays for predicting the…
Transplantation versus novel therapies in high-risk chronic lymphoblastic leukemia (CLL)?
John Gribben, MD, DSc, FRCPath, FMed Sci, from Barts Cancer Institute, London, UK, discusses transplantation versus novel therapies for the…
Is double autologous transplantation in multiple myeloma superior in the age of new agents?
Jean-Luc Harousseau, MD, from the University of Nantes, Nantes, France, discusses the use of double autologous transplantation in multiple myeloma…
Waldenstrom macroglobulinemia: Treatment methods and clonal evolution
Irene Ghobrial, MD of the Dana-Farber Cancer Institute, Boston, discusses the advances made in the treatment of Waldenstrom macroglobulinemia and…
Highlights from the EBMT 2017 cell therapy day
Christian Chabannon, MD, PhD, from Institut Paoli Calmettes, Marseille, France, discusses highlights of cellular therapy presented at the 2017 annual…
Improving the outcomes of transplantation with bispecific antibodies
Hermann Einsele, MD, from the University Hospital Würzburg, Würzburg, Germany, discusses the use of bispecific antibodies before and after allogeneic…
Can transplant quality be improved by training medical personnel?
Riccardo Saccardi, MD, from Careggi University Hospital, Florence, Italy, discusses education for physicians about transplantation at the 2017 annual meeting…
What are the advantages of multiple myeloma maintenance therapy?
Laurent Garderet, MD, from the Saint-Antoine Hospital, Paris, France, explains that up-front autologous stem cell transplant is still the gold…
Sign up for the latest news and videos
Is CLL curable today?
How far are we from a cure for CLL?
Mechanism of action of venetoclax (ABT-199) and its side effects
Myeloma 2016: Panel discussion on novel treatments
Highlights from the International Workshop of the German CLL Study Group